Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for patients with cancer. The company operates within the biotechnology and oncology drug development industries, with a strategy centered on precision medicines designed to selectively inhibit specific oncogenic targets while minimizing off-target toxicity.
The company’s primary revenue drivers are its internally developed drug candidates, as it does not currently generate commercial product revenue. Enliven’s pipeline focuses on kinase inhibitors for genetically defined cancers, targeting patient populations with high unmet medical needs. The company positions itself through a structure-based drug design approach intended to improve safety and efficacy relative to earlier-generation therapies. Enliven Therapeutics was founded in 2019 and advanced its platform rapidly, culminating in an initial public offering in 2023 to fund clinical development and pipeline expansion.
Business Operations
Enliven Therapeutics operates as a single-reportable-segment company focused on oncology research and development, generating value through the advancement of proprietary drug candidates into clinical trials. Its core assets include ELVN-001, a small-molecule inhibitor targeting BCR-ABL for chronic myeloid leukemia, and ELVN-002, a HER2-selective inhibitor for solid tumors. The company’s operations are primarily pre-commercial, with expenditures focused on R&D, clinical trials, and regulatory activities.
The company’s operations are primarily domestic, with clinical trial activities conducted both in the United States and internationally through contract research organizations. Enliven controls its intellectual property portfolio internally and does not currently report material revenue from collaborations. As of the latest public disclosures, the company does not report any material subsidiaries, joint ventures, or revenue-generating partnerships.
Strategic Position & Investments
Enliven Therapeutics’ strategy centers on advancing a focused oncology pipeline through clinical proof-of-concept while maintaining capital discipline. Growth initiatives include progressing lead programs through mid-stage clinical development and expanding its discovery engine to identify additional precision oncology candidates. The company emphasizes differentiation through molecular selectivity and mutation-specific targeting.
The company has not announced major acquisitions since inception and primarily invests in internal research capabilities. Its strategic investments are concentrated in early- and mid-stage clinical trials, manufacturing readiness, and regulatory preparation. Enliven remains focused on emerging targeted oncology therapies rather than diversification into non-core therapeutic areas.
Geographic Footprint
Enliven Therapeutics is headquartered in the United States, with principal offices in Colorado. Its operational footprint is primarily North American, though its clinical development activities extend into Europe and other international regions through global trial sites and third-party service providers.
The company does not maintain significant owned international infrastructure but has an international presence through clinical operations and regulatory engagement. Its geographic strategy emphasizes access to diverse patient populations and alignment with major oncology research centers.
Leadership & Governance
Enliven Therapeutics was founded by experienced biotechnology executives and drug developers with prior success in oncology-focused companies. The leadership team emphasizes scientific rigor, patient-centric development, and disciplined capital allocation as core elements of its governance philosophy.
Key executives include:
- Sam Kintz, PhD – President & Chief Executive Officer
- Data inconclusive based on available public sources for additional executive leadership roles, as disclosures beyond the CEO vary across public filings and investor materials and cannot be consistently verified across independent sources.